Figure 2: mCuMVTT-RBM induces high levels of
specific antibodies with high avidity against RBD and Spike proteins of
SARS-CoV-2
A, Vaccination regimen D0/14 or D0/28 and bleeding schedule. B,
RBD-specific IgG titer for the groups vaccinated with
CuMVTT as a control or mCuMVTT-RBM on
days 7, 14, 21, 28, 35 and 42 measured by ELISA OD450.
C, Log OD50 of RBD-specific IgG titer for the group
vaccinated with mCuMVTT-RBM on days 7, 14, 21, 28, 35
and 42 (Data from B). D, Spike-specific IgG titer for the groups
vaccinated with CuMVTT as a control or
mCuMVTT-RBM on days 7, 14, 21, 28,3 5 and 42 measured by
ELISA OD450. E, Log OD50 of
spike-specific IgG titer for the group vaccinated with
mCuMVTT-RBM on days 7, 14, 21, 28, 35 and 42 (Data from
D). F, Avidity of RBD-specific IgG titer in mice vaccinated with
mCuMVTT-RBM using D0/14 vaccination regimen, sera were
treated with PBST or 7M Urea. G, Avidity of RBD-specific IgG titer in
mice vaccinated with mCuMVTT-RBM using D0/28 vaccination
regimen, sera were treated with PBST or 7M Urea. H, Avidity index of
RBD-specific IgG in mice vaccinated with mCuMVTT-RBM
using D0/14 vaccination regimen, sera were treated with PBST or 7M Urea.
L, RBD-specific IgG titer for the group vaccinated with
mCuMVTT-RBM on days 42 and 134. M, Spike-specific IgG
titer for the group vaccinated with mCuMVTT-RBM on days
42 and 134. Statistical analysis (mean ± SEM) using Students
t-test , n=10. One representative of 3 similar experiments is shown. The
value of p <0.05 was considered statistically
significant (*p <0.01, **p <0.001,
***p <0.0001).